Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Sarcoma, Kaposi 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Hematologic Neoplasms 1Graft vs Host Disease 1Colorectal Cancer Metastatic 1

Interventions

Bevacizumab 17Capecitabine 13Cetuximab 10Oxaliplatin 8Irinotecan 8Fluorouracil 7Panitumumab 5Leucovorin 4trifluridine tipiracil drug combination 3sintilimab 3regorafenib 3Nivolumab 3Ipilimumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Folfox protocol 2Drug Therapy 2spartalizumab 1pembrolizumab 1irinotecan sucrosofate 1glucopyranosyl lipid-A 1folfirinox 1camrelizumab 1balstilimab 1anisodamine 1aflibercept 1XELOX 1Vemurafenib 1Tyrosine Kinase Inhibitors 1Transurethral Resection of Prostate 1Tomography, X-Ray Computed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Cancer Metastatic × Maraviroc × Clear all
NCT04721301 2023-10-17

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

University Hospital Heidelberg

Phase 1 Completed
50 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡